
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Click the title above for a link to open the Pharmaceutical Executive March 2024 issue in an interactive PDF format.
over 2 years ago
How’s Business?over 2 years ago
Eyeing Efficiency for Allover 2 years ago
Positioning Medical Information as a Trust Driver for Your Brandover 2 years ago
Straight and Simple Advice Lives On in the Pharma Industryover 2 years ago
A Return to the Fundamentals in Biotech Investment?over 2 years ago
The Shifting Landscape of the Life Sciences Job Marketalmost 3 years ago
Copay Adjustment Programs: What’s Next for Manufacturers?





